Home/Pipeline/ITK inhibitor

ITK inhibitor

Atopic dermatitis

Pre-clinicalHit-to-Lead

Key Facts

Indication

Atopic dermatitis

Phase

Pre-clinical

Status

Hit-to-Lead

Company

Acellera

About Acellera

Acellera's mission is to transform drug discovery into a high-accuracy, computable task by developing algorithms that automate the process. Founded in 2016, the company has built a robust technology stack, including the QuantumBind® platform and open-source tools like ACEMD, OpenMM, and ACEGEN, backed by over 18 years of computational know-how and thousands of academic citations. While currently a private company with no external investment, Acellera is developing an internal pipeline of drug candidates and plans to raise funding in 2026 to scale its ambitious goals.

View full company profile

Therapeutic Areas

Oncology Immunology Inflammatory Diseases Infectious Diseases Neurology

Other Atopic dermatitis Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
HBM7575 (SKB575)	Harbour BioMed	IND Filed	Active (Global)
Encube-003	Encube Ethicals	Preclinical	Active
ENS-002 (Fermata Derm)	Concerto Biosciences	Pre-clinical	Active
Lead Program	MatriSys Bioscience	Phase 1	Active
Atopic Dermatitis Trial	Well Pharma Medical Research	Not Specified	Active
MEndoB	Micreos	Pre-clinical	Active
Atopic Dermatitis Program	Lxbio Pharmaceuticals	Pre-clinical	Active
B244	AOBiome	Phase 3	Active
CTO1681	CytoAgents	Pre-clinical	Active
DS107	DS Biopharma	Phase 2	Active
AX-158	Artax Biopharma	Phase 2	Active